Documentdetail
ID kaart

oai:pubmedcentral.nih.gov:1114...

Onderwerp
Review Article
Auteur
Zimmer, Julia Mahler, Vera
Langue
en
Editor

Dustri-Verlag Dr. Karl Feistle

Categorie

Allergologie Select

Jaar

2024

vermelding datum

10-06-2024

Trefwoorden
framework regulatory products allergen development
Metriek

Beschrijving

Development, production, and marketing authorization of allergen products is generally challenging due to several specific characteristics, including the natural source as well as the multitude of allergenic materials.

Also, depending on the frequency of sensitization in the population, the number of patients available for inclusion in clinical trials can be a limiting factor for product development.

In the development of allergen products for diagnosis of type I and type IV allergies these challenges are particularly demanding because, in contrast to certain products for allergen-specific immunotherapy, no exemptions from marketing authorization are foreseen for this product group in Directive 2001/83/EC.

Thus, the regulatory framework is constantly adapted within the legal scope in order to balance necessary regulatory requirements ensuring quality, safety, and efficacy with the clinical need for a comprehensive range of diagnostic allergen products.

In this article, we give an overview on the current regulatory framework for development and marketing authorization of allergen products for diagnosis of rare type I and type IV allergies.

Zimmer, Julia,Mahler, Vera, 2024, Regulatory framework for development and marketing authorization of allergen products for diagnosis of rare type I and type IV allergies: The current status, Dustri-Verlag Dr. Karl Feistle

Delen

Bron

Artikelen aanbevolen door ES/IODE AI

A rare case of localized peliosis hepatis during adjuvant chemotherapy including oxaliplatin mimicking a liver metastasis of colon cancer
peliosis hepatis metastatic liver tumor oxaliplatin oxaliplatin associated cancer metastatic tumor liver hepatis peliosis